Background: Neuroendocrine tumors (NETs) are an unusual family of neoplasms with a wide and complex spectrum of clinical behavior. Here, we present the first report of a National Cancer Registry of gastroenteropancreatic neuroendocrine tumors from a Southern European country.
The incidence of NETs ranges from 2.5 to 5 cases per 100 000 in Caucasian population [7] [8] [9] [10] . The reported incidence has substantially increased over the last decades, partially due to improved diagnostic techniques and clinical awareness. However, incidence rates overall and per individual anatomic site are widely variable in the literature. Many issues may account for these discrepancies, including differences in patient selection, specific institutional or registration biases, racial disparities and other as yet unknown genetic and environmental factors. These issues along with patterns of care may greatly differ across countries and may ultimately influence outcome in a significant way.
To provide information regarding demographic characteristics, diagnostic procedures, tumor features, therapeutic interventions and survival of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a national tumor registry was launched in 2001 by GETNE, the Spanish Scientific Society of Neuroendocrine Tumors. We present here the results of this broad-based multi-institutional registry that comprises 46 academic and community sites representing all regions of Spain. To date, published data mostly refer to United States, UK and Northern European populations [7] [8] [9] [10] [11] [12] [13] [14] [15] . This is to our knowledge the first study providing information on this type of tumors from a Southern European country.
patients and methods
The study population was obtained from the National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors (RGETNE). RGETNE was launched by the scientific society GETNE, which is composed by specialists from multiple disciplines (oncologists, 77%; endocrinologists, 18%; surgeons, 4%; pathologists; biologists; .) and leads at the national level multiple educational and research projects on NETs. This broad-based multi-institutional registry comprises 46 academic and community sites representing all regions of Spain (Appendix 1). Data collection was provided online at www.retegep.net by investigators or study nurses from participating institutions and assessed for internal consistency by external independent reviewers. The registry database and standard operating procedures were approved by a National Scientific and Ethics Committee.
From June 2001 through December 2008, 907 tumors from 887 patients were prospectively registered. Only patients with survival data have been included in this report (855 tumors and 837 patients). The medical records were systematically reviewed to collect the following data: age, gender, functional syndrome, familial hereditary syndrome, diagnostic procedures, localization of the primary tumor, histopathological features (World Health Organization classification [16] , immunohistochemical staining, grade and vascular invasion), tumor stage at diagnosis, therapeutic interventions and outcomes (surgery, local-regional therapies, hormone therapy, chemotherapy, radiotherapy and radionuclide therapy), date of diagnosis, date of relapse or disease progression, date of last visit or death and cause of death. Tumor stage was classified as localized (confined to the organ of origin), regional (invasion of surrounding organs or tissues or regional lymph nodes) or distant (spread to distant organs). Number (i.e. single or multiple) and size of primary tumors and specific sites of distant metastasis were also recorded.
Descriptive statistics were used to characterize the most relevant clinical parameters. The association of categorical variables was assessed by the chisquare test or Fisher's exact test when appropriate. One-way analysis of variance was used for comparison of continuous variables between groups.
Overall survival was defined as the time elapsed from the date of diagnosis to the date of death from any cause or last follow-up in alive patients. Survival was estimated according to the Kaplan-Meier product limit method, and differences observed among patient subgroups were assessed by the log-rank test. Multivariate analyses using the Cox proportional hazards model were carried out to identify factors independently associated with prognosis. Gender, age, hormonal syndrome, stage, Ki-67, tumor type and localization of primary tumor were included as covariates in the model. Two-sided P values were computed; P <0.05 was considered statistically significant. All analyses were carried out using the SPSS statistical package (SPSS version 16.0 for Windows; SPSS Inc., Chicago, IL).
results

patient population
Of 837 assessable patients with GEP-NETs, 458 (55%) were men and 379 (45%) were women. The median age at diagnosis was 59 years (range 10-99 years), and 25% presented with hormone hypersecretion symptoms, with no significant differences according to gender (Table 1) . Appendix primaries and functional tumors were diagnosed at younger ages (median age at diagnosis: appendix primary, 42 years; insulinoma, 48 years and gastrinoma, 52 years). Multiple endocrine neoplasia was diagnosed in 43 patients (5%). Of them, 91% had hyperparathyroidism, 42% pituitary adenomas, 23% adrenal adenomas and 5% pheochromocytomas. Both adrenal adenomas (30% versus 17%) and pheochromocytomas (10% versus 0%) were more commonly observed in men as compared with women.
diagnostic procedures
Incidental diagnosis occurred in 22% of cases. The most commonly carried out imaging studies included computed tomography (CT) scan, ultrasound and somatostatin receptor scintigraphy (octreotide scintigraphy). CT scan was the procedure with the highest yield of tumor detection (75%). OctreoscanÒ was done in 49% of patients and 81% of them were positive. Only about one-third of the registered patients underwent endoscopic procedures. Biochemical tests such as serum chromogranin A or urinary 5-hydroxyindole acetic acid (5-HIAA) levels were only done in 41% and 27% of the population and were increased in 67% and 45% of tested patients, respectively. Immunohistochemical staining for chromogranin and synaptophysin was done in 66% and 50% of tumors, being positive in 93% and 96% of reported cases, respectively. Ki-67 index was carried out in only 36% of tumors. Other diagnostic procedures are summarized in Table 2 .
tumor characteristics
The most common tumor types were gastrointestinal carcinoids (55%), followed by pancreatic nonfunctional tumors (20%) and metastatic NETs of unknown primary (9%) ( Table 3) . Among functional tumors, enteric carcinoids (10%), insulinomas (8%) and gastrinomas (4%) were the most commonly encountered. Glucagonomas, vasoactive intestinal peptidomas (VIPomas) or somatostatinomas were found in <2% of the population. The gastrointestinal tract was the primary tumor site in 400 patients (47%), the pancreas in 288 patients (34%) and in 167 patients (20%), primary tumor site was unknown or not registered. Among enteric tumors, small intestine (16%), appendix (9%) and stomach (6%) were the most frequent sites of origin. Neither the distribution of tumor types nor primary tumor localizations varied significantly by gender, although there was a slightly higher incidence of insulinomas in women and of colon primary tumors in men (Table 3) . At diagnosis, tumors were localized in 36% of the patients, had regional spread in 14% and had distant metastases in 44%. Over one-third of them had tumors >2 cm (17% >4 cm). Fifty-six patients (7%) presented multiple primary tumors and 17 (2%) had several NET types. Ki-67 index was <2% in 44% of assessed tumors and >20% in 18%. The most common site of distant metastases was liver (42%), followed by distant lymph nodes (10%), peritoneum (7%), bone (5%) and lung (3%).
Women tended to have earlier tumor stages than men (42% versus 32% had localized disease). Stage at diagnosis was also significantly different depending upon localization of primary tumor, tumor type and grade ( Table 4 ). The primary tumor sites that presented most frequently with distant disease at diagnosis included small intestine (65%), colon (48%), rectum (40%) and pancreas (38%), whereas it was most unusual in appendix primaries (1.3%). The tumor types most commonly associated with widespread disease were VIPomas (71%), pancreatic nonfunctioning tumors (44%) and bowel carcinoids (41%), as opposed to gastrinomas (22%), insulinomas or glucagonomas (15% each). As expected, poorly differentiated tumors were more prone to have distant metastasis at diagnosis (67%), although the proportion of patients with well-differentiated tumors and stage IV disease at presentation was also rather high (38%).
therapeutic interventions
Overall, about two-thirds of the patients underwent surgery, most of them with curative intent (65%) but also with palliative purposes (14%). The proportion was higher among patients with local (85%) or regional (95%) disease but still remarkable in patients with widespread tumors (48%). Surgical resection of the primary tumor was carried out in 84% and 45% of patients with local versus distant disease, respectively. One hundred and twenty-nine patients underwent resection of metastatic disease: 27 patients had surgery of metachronous and 92 of synchronous metastases (Table 5) . Local-regional therapies such as embolization, chemoembolization, radiofrequency or other ablative techniques were uncommon (<5% of the population). Three hundred and seventy-two patients (44%) received some kind of systemic therapy at some point along the course of the disease: 29% received somatostatin analogues, 9% interferon and 25% chemotherapy. These percentages were substantially higher among patients that presented with advanced disease (51% somatostatin analogues, 17% interferon and 41% chemotherapy). The somatostatin analogue most commonly used was octreotide (30% of patients versus 14% lanreotide). The cytotoxic drugs most frequently employed were platinum compounds (113 patients, 18.1%), etoposide (99 patients, 15.8%), streptozotocin (91 patients, 14.6%), fluoropyrimidines (88 patients, 14.1%), anthracyclines (53 patients, 8.5%), taxanes (15 patients, 2.4%), gemcitabine (10 patients, 1.6%), topoisomerase I inhibitors (7 patients, 1.1%), dacarbazinetemozolomide (4 patients, 0.6%) and mTOR inhibitors and antiangiogenics (4 patients each, 0.6%). The most common chemotherapy combination regimens used as first-line therapy included platinum-etoposide (93 patients, 14.9%), streptozotocin-5-fluorouracil (5-FU) (50 patients, 8.0%), doxorubicin-streptozotocin (37 patients, 5.9%), doxorubicin/ 5-FU (2 patients, 0.3%), doxorubicin-streptozotocin-5-FU (3 patients, 0.5%), oxaliplatin-fluoropyrimidine (6 patients, 1.0%), paclitaxel-carboplatin (6 patients, 1.0%) and docetaxelgemcitabine (4 patients, 0.6%).
survival and prognostic factors
At the last follow-up, 157 patients had died (19%). The median overall survival for all registered patients was 12 years (range 0.1-24.8 years), with 75.5% of patients alive at 5 years (95% confidence interval 71.4% to 79.6%). The main causes of death were tumor related (77%), treatment related (7%), due to other neoplasia (3%) or due to medical complications unrelated to tumor or therapy (12%). Sixty-one patients (7%) developed other non-neuroendocrine malignant neoplasia, which included 28 gastrointestinal tumors (22 colorectal, 4 biliopancreatic and 1 gastric adenocarcinomas), 15 genitourinary malignancies (5 urothelial carcinomas, 4 prostate adenocarcinomas, 4 clear-cell renal carcinomas, 1 Sertoli cell testicular tumor and 1 penis carcinoma), 9 gynecological cancers (3 breast, 3 ovarian, 2 endometrial and 1 cervical carcinomas), 4 head and neck tumors (1 meningioma, 1 neurinoma, 1 laryngeal and 1 follicular thyroid carcinoma), 3 hematological malignancies (1 multiple myeloma, 1 lymphoma and 1 leukemia) and a liposarcoma. Overall survival was significantly greater in women, younger patients and patients with hormonal syndrome and in early stage or lower grade tumors (Table 6 ) (Figure 1 ). Prognosis also differed significantly according to tumor type (insulinoma/gastrinoma > glucagonoma/VIPoma > carcinoid/nonfunctional pancreatic tumor > metastasis of unknown primary) or to localization of primary tumor (appendix > duodenum > jejunum-ileum > pancreas > colon > rectum > stomach) ( Table 6 ). Survival rates according to disease stage for different tumor types and primary tumor locations are provided in Table 7 . Multivariate analysis confirmed stage and Ki-67 index as the only independent prognostic factors for survival (Table 8) .
discussion
This study is relevant as it is to our knowledge the first providing comprehensive information on the incidence, management and outcome of this type of tumors from a Southern European country. Indeed, most reported data to date refer to the USA population and some Northern or Central European countries. As racial composition and other genetic and environmental factors, as well as availability of health care resources and institutional and registration biases may greatly differ among different patient populations, the present study may provide valuable insights which may help understand regional disparities in epidemiology, patterns of care and survival of NETs across different continents and countries. This study confirms that NETs are a broad family of tumors with a wide range of clinical presentations and outcomes. Although more indolent than carcinomas, indeed the overall survival of our series was 75% at 5 years, the prognosis was highly variable from 100% for appendix primaries to <30% for poorly differentiated tumors. There was a slight preponderance of males in our series (versus a slight women preponderance in other series) [7, 8] , although sex ratio was close to 1. As expected, the gastrointestinal tract was the primary tumor site in 400 patients (47%), the pancreas in 288 patients (34%) and in 167 patients (20%), primary tumor site was unknown or not registered. However, among enteric carcinoids, primary tumor site distribution in our series significantly differed with that observed in the Surveillance, Epidemiology and End Results (SEER) Program tumor registry. While the rectum was the most common gastrointestinal tumor primary in the USA NET, neuroendocrine tumors; HP, hormone production; VIPoma, vasoactive intestinal peptidoma; NOS, not otherwise specified; NR, not reported.
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Annals of Oncology population, particularly in Asian/Pacific Islander, American Indian/Alaskan Native and African-American patients, in our cohort, the most frequent sites of origin were the small intestine followed by the appendix and stomach, whereas the rectum only accounted for 6% of tumor cases [7] . Registries from Northern European countries, which as Spain have predominantly white Caucasian population, also find small intestine as the most common primary site of intestinal NETs [8] . A significant proportion of patients (44%) in our national registry presented with widespread disease at diagnosis compared with other series (21% in SEER database). Several potential explanations may justify this difference. First of all, the fact that the great majority of GETNE Society members (77%) are medical oncologists may introduce some registration bias as they generally deal with more advanced cases than endocrinologists, gastroenterologists or surgeons. On the other hand, a notably high proportion of patients in the SEER Registry had unknown stage (20%) versus only 5% in our series [7] . Nevertheless, a later diagnosis in our country possibly caused by poorer availability of health care resources cannot be excluded and is of concern particularly in this disease where surgery is the primary means of cure. However, this hypothesis is not consistent with the fact that despite more advanced disease, the overall survival of our cohort is in the upper range of that previously reported in other series. Stage migration due to improved diagnostic techniques, which would be expected in a more recent series like ours, could potentially explain these observations.
A strong correlation was observed, as in the SEER Registry, between primary tumor site and disease stage. However, some discrepancies in this association between both series shall be remarked. Whereas in our cohort, the most common primary tumor sites associated with widespread disease at diagnosis were jejunum/ileum (65%), colon (48%) and rectum (40%); in the SEER Registry, these included pancreas (64%), cecum/ colon (44%/32%) and jejunum/ileum (30%). Early-stage gastric and rectal tumors are likely underrepresented in the Spanish registry as there is a low participation of gastroenterologists in the National Scientific Society of Neuroendocrine Tumors (GETNE). Tumor type was also significantly associated with stage at diagnosis: a higher proportion of VIPomas (71%), pancreatic nonfunctional tumors (44%) and enteric carcinoids (41%) presented with stage IV disease, compared with gastrinomas (22%), insulinomas or glucagonomas (15% each). As expected, poorly differentiated tumors were more prone to have distant metastases at diagnosis (67%), although the proportion of patients with well-differentiated tumors and stage IV disease at presentation was also rather high (38%). Finally, a trend toward a more localized disease and improved survival was observed in women.
The present study also provides one of the most comprehensive reports on diagnostic and therapeutic procedures used in current clinical practice in this patient population. Of note, specific biochemical tests or immunohistochemical stainings were greatly infra-utilized. Although the high rate of incidental diagnosis (22%) may partially explain why only 41% and 27% of patients had serum chromogranin A or urinary 5-HIAA levels tested at diagnosis, a low use of immunohistochemical staining for chromogranin, synaptophysin and Ki-67 index, which were only carried out in 66%, 50% and 36% of tumors, respectively, was also observed. These figures probably reflect the low referral rate of patients to specialized centers in our country. Regarding therapeutic interventions, however, there was an extensive and appropriate use of surgery and systemic therapies in all disease stages, although a low use of local-regional ablative approaches again most likely reflecting a low number of referrals. The nonavailability of radionuclide therapy in Spain justifies the fact that only 1% of the patients received this therapeutic modality.
Overall prognosis was favorable, with a 5-year survival rate of 75%. This figure, however, may be somewhat overestimated due to insufficient follow-up in the context of a slow growing disease with a high rate of late events. Indeed, despite the relatively indolent nature of these tumors, as compared with gastrointestinal carcinomas, once the tumor has progressed beyond surgical resectability, the disease is eminently incurable. In this regard, it is remarkable that 77% of deaths in our cohort were due to tumor progression and an additional 7% were due to treatment-related issues (drug toxicity, surgical complications). Survival was significantly greater in women, younger patients and patients with hormonal syndrome and in early stage or lower grade tumors. As observed by others, prognosis also differed significantly according to tumor type or to primary tumor site, although with some striking differences compared with other geographical regions (i.e. poorer survival for gastric or rectal primaries in our country). However, stage and grade remained the only independent predictors for outcome in multivariate analysis, which underscores the need for earlier diagnosis and for improved systemic therapies for advanced disease. This national database reveals relevant information regarding current clinical practices and provides valuable insights into the epidemiology and outcome of this heterogeneous and not so uncommon disease. Indeed, GEP-NETs are more prevalent and lethal than previously thought. Despite some recent progress [17] [18] [19] [20] [21] [22] , patient survival has not significantly changed over the last 30 years. Improving our understanding of the molecular basis of this disease, as well as the mechanisms involved in response and resistance to therapy, will be essential tools that will help us develop early diagnosis tools and newer more rationally designed treatment strategies that will potentially change the natural history of malignant NETs. Finally, encouraging physicians to refer these patients to specialized centers and patients to participate in clinical trials is of utmost importance.
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